Pharmaceutical Manufacturing Plan for Africa

Date of commitment: 
October 2007


Pursue, with the support of partners, the local production of generic medicines on the continent and to make full use of the flexibilities within the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the WTO Doha Declaration on TRIPS and Public Health.


No numerical targets were set.
Indicator of progress: consideration by African governments of legislative reforms of domestic IP statutes and regulations.


There are some indications that safe and effective medicines can be produced in low- and middle-income countries. The importance of developing local production of pharmaceuticals has also been recognized as a priority at the national level by, for instance, Botswana, Ghana, Kenya and the United Republic of Tanzania. With the exception of South Africa, local production in sub-Saharan Africa is currently limited to manufacturing final formulations, which include analgesics, simple antibiotics and vitamins. Only a few local producers have managed to satisfy WHO pre-qualification requirements that allow them to compete under procurement schemes of medicines funded by international donors to fight AIDS, tuberculosis and malaria. However, Kenyan producers have managed to achieve certification under the Pharmaceutical Inspection Co-operation Scheme (PICS).


No numerical targets were set, thus it is difficult to measure a gap.


Not new commitment.